# 2026-09283: FDA Calls Vets and Drug Makers to Animal Fee Renewal Talks

2026-09283, Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-11, effective 2026-06-01; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09283
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09283
- Title: Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 25576
- Published: 2026-05-11
- Effective: 2026-06-01
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Calls Vets and Drug Makers to Animal Fee Renewal Talks

## Summary

The FDA is inviting vets, animal drug makers, and animal lovers to join meetings about renewing the Animal Drug User Fee Act before it expires in 2028. These meetings, starting June 2026 and happening every four months, will help decide how fees for animal drug reviews are set and used. If you want to have a say, let the FDA know by June 1, 2026!

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is issuing this notice to request that public stakeholders notify FDA of their intent to participate in periodic consultation meetings on reauthorization of the Animal Drug User Fee Act (ADUFA). The statutory authority for ADUFA expires September 30, 2028. The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that FDA consult with a range of stakeholders--including patient and consumer advocacy groups, veterinary professionals, and scientific and academic experts--in developing recommendations for the next ADUFA program and hold discussions with these stakeholders at least once every 4 months during FDA's negotiations with the regulated industry. The purpose of this request for notification is to ensure consistent stakeholder representation at the consultation meetings.

## Effects PRIA read

- Stakeholder Sign‑up Deadline: June 1, 2026: benefit, low. If you represent a stakeholder group (veterinary professionals, patient and consumer advocacy groups, or scientific and academic experts) and want to join FDA’s ADUFA reauthorization discussions, notify FDA by email at [email protected] by June 1, 2026. Stakeholders who notify will be included in f…
- Scheduled Consultation Meetings Starting June 2026: benefit, low. FDA will hold stakeholder consultation meetings beginning in June 2026 and will continue meeting at least once every 4 months during ADUFA reauthorization negotiations. Meetings will be held in person at the FDA Harvey W. Wiley Federal Building, 5001 Campus Drive, College Park, MD 20740, and virtua…
- ADUFA Authority Ends September 30, 2028: cost, medium. The current Animal Drug User Fee Act authority (ADUFA V) expires September 30, 2028. The notice states that without new legislation to reauthorize the program, FDA will no longer be able to collect user fees for future fiscal years to fund the new animal drug review process.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09283 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/11/2026-09283/animal-drug-user-fee-act-stakeholder-consultation-meetings-on-the-animal-drug-user-fee-act)
- [2026-09283 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-11/pdf/2026-09283.pdf)

## Related
- [Previous: 2026-09281, Submission for OMB Review; Comment Request](https://policyrisk.com/federal-register/2026-09281)
- [Next: 2026-09284, Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Anim…](https://policyrisk.com/federal-register/2026-09284)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09283 (as of 2026-06-08).
